Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.


Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 24 05 2018
accepted: 28 09 2018
pubmed: 18 11 2018
medline: 16 4 2019
entrez: 18 11 2018
Statut: ppublish

Résumé

Atypical teratoid/rhabdoid tumor (ATRT) is a highly malignant brain tumor predominantly arising in infants. Mutations of SWI/SNF chromatin remodeling complex members SMARCB1/INI1 or (rarely) SMARCA4/Brg1 are the sole recurrent genetic lesions. Epigenetic studies revealed a large number of genes predicted to be affected by differential histone modifications in ATRT, but the role of these genes in the biology of ATRT remains uncertain. We therefore aimed at exploring the role of these genes in the detrimental effects of SMARCB1-deficiency. The functional relevance of 1083 genes predicted to be affected by epigenetic alterations in ATRT was examined in vivo using a Drosophila melanogaster model of SMARCB1-deficiency. Human orthologues of genes whose knockdown modified the phenotype in the Gal4-UAS fly model were further examined in ATRT samples and SMARCB1-deficient rhabdoid tumor cells. Knockdown of Snr1, the fly orthologue of SMARCB1, resulted in a lethal phenotype and epigenetic alterations in the fly model. The lethal phenotype was shifted to later stages of development upon additional siRNA knockdown of 89 of 1083 genes screened in vivo. These included TGF-beta receptor signaling pathway related genes, e.g. CG10348, the fly orthologue of transcriptional regulator PRDM16. Subsequently, PRDM16 was found to be over-expressed in ATRT samples and knockdown of PRDM16 in SMARCB1-deficient rhabdoid tumor cells reduced proliferation. These results suggest that a subset of genes affected by differential histone modification in ATRT is involved in the detrimental effects of SMARCB1-deficiency and also relevant in the biology of ATRT.

Identifiants

pubmed: 30446899
doi: 10.1007/s11060-018-03018-6
pii: 10.1007/s11060-018-03018-6
doi:

Substances chimiques

DNA-Binding Proteins 0
Drosophila Proteins 0
Histones 0
PRDM16 protein, human 0
SMARCB1 Protein 0
SMARCB1 protein, human 0
Snr1 protein, Drosophila 0
Transcription Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-55

Subventions

Organisme : IZKF
ID : Ha3/019/15
Organisme : Deutsche Forschungsgemeinschaft
ID : HA3060/5-1

Références

Blood. 2000 Nov 1;96(9):3209-14
pubmed: 11050005
Biotechniques. 2003 Feb;34(2):374-8
pubmed: 12613259
Int J Cancer. 2003 Aug 20;106(2):244-51
pubmed: 12800201
Blood. 2003 Nov 1;102(9):3323-32
pubmed: 12816872
Blood. 2004 Apr 1;103(7):2753-60
pubmed: 14656887
Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12129-34
pubmed: 16099835
Neurogenetics. 2006 May;7(2):67-80
pubmed: 16572319
Biochim Biophys Acta. 2007 Jun;1773(6):814-20
pubmed: 17467076
Cell Metab. 2007 Jul;6(1):38-54
pubmed: 17618855
J Clin Invest. 2007 Dec;117(12):3696-707
pubmed: 18037989
PLoS One. 2008 Aug 28;3(8):e3088
pubmed: 18769486
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
J Biol Chem. 2009 Jan 30;284(5):3334-44
pubmed: 19049980
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
J Pathol. 2009 May;218(1):86-94
pubmed: 19197950
Clin Cancer Res. 2009 Mar 15;15(6):1923-30
pubmed: 19276269
Am J Pathol. 2009 Oct;175(4):1631-7
pubmed: 19717644
Am J Hum Genet. 2010 Feb 12;86(2):279-84
pubmed: 20137775
Neuro Oncol. 2011 Dec;13(12):1296-307
pubmed: 21946044
Bioessays. 2012 Jan;34(1):50-60
pubmed: 22028065
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
Nat Genet. 2012 Jan 29;44(3):251-3
pubmed: 22286216
Nature. 2012 Aug 2;488(7409):43-8
pubmed: 22722829
Pediatr Blood Cancer. 2012 Dec 15;59(7):1155-7
pubmed: 22997201
Genes Chromosomes Cancer. 2013 Feb;52(2):185-90
pubmed: 23074045
Nat Rev Cancer. 2013 Mar;13(3):172-83
pubmed: 23388617
BMC Cancer. 2013 Jun 13;13:286
pubmed: 23764045
Nat Commun. 2014 Jun 03;5:4005
pubmed: 24892285
Nature. 2014 Aug 7;512(7512):91-5
pubmed: 24896182
Acta Neuropathol. 2014 Sep;128(3):453-6
pubmed: 25060813
Mol Cell. 2015 Jan 22;57(2):235-46
pubmed: 25578880
Oncotarget. 2015 Feb 20;6(5):3165-77
pubmed: 25638158
Neuro Oncol. 2016 Jun;18(6):764-78
pubmed: 26755072
Cancer Cell. 2016 Mar 14;29(3):379-393
pubmed: 26923874
Curr Opin Genet Dev. 2016 Feb;36:83-91
pubmed: 27153352
Cancer Cell. 2016 Dec 12;30(6):891-908
pubmed: 27960086
J Neurooncol. 2017 Feb;131(3):477-484
pubmed: 28108836
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
Neuropathology. 2018 Jun;38(3):305-308
pubmed: 29271065
Endocrinology. 2018 Jul 1;159(7):2520-2527
pubmed: 29757434
Cancer Res. 1999 Jan 1;59(1):74-9
pubmed: 9892189

Auteurs

Isabel Tegeder (I)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany.

Katharina Thiel (K)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany.

Serap Erkek (S)

Hopp-Children's Cancer Center at the NCT Heidelberg, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Pascal D Johann (PD)

Hopp-Children's Cancer Center at the NCT Heidelberg, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
Department of Pediatric Oncology and Hematology, University Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.

Johannes Berlandi (J)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany.

Venu Thatikonda (V)

Hopp-Children's Cancer Center at the NCT Heidelberg, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Michael C Frühwald (MC)

Children's Hospital Augsburg, Swabian Children's Cancer Center, Stenglinstr. 2, 86156, Augsburg, Germany.

Marcel Kool (M)

Hopp-Children's Cancer Center at the NCT Heidelberg, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Astrid Jeibmann (A)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany.

Martin Hasselblatt (M)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany. hasselblatt@uni-muenster.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH